| Name | 2-(butan-2-yldisulfanyl)-1H-imidazole |
|---|---|
| Synonyms |
2-(butan-2-yldisulfanyl)-1H-imidazole
IV-2 compound UNII:8PQ9CZ8BTJ 1-methylpropyl 2-imidazolyl disulfide PX 12 1-methyl-1-propyl 2-imidazolyl disulfide 2-(sec-Butyldisulfanyl)-1H-imidazole 1-methylpropyl 2-mercaptoimidazolyl disulfide 2-[(1-Methylpropyl)dithio]-1H-imidazole 1H-Imidazole, 2-[(1-methylpropyl)dithio]- PX-12 |
| Description | PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (Trx-1); inhibits the growth of MCF-7 and HT-29 cells with IC50 values of 1.9 and 2.9 μM, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.9 (MCF-7), 2.9 μM (HT-29 cells)[1] |
| In Vitro | PX-12 inhibits the growth of MCF-7 and HT-29 cells with IC50 values of 1.9 and 2.9 μM, respectively[1]. PX-12 particularly reduces the activity of Trx-1 by means of thio-alkylating critical cysteine residue (Cys73) which is located in the outside the conserved redox catalytic site of Trx-1. PX-12 affects the oxidation state of thiols in a number of cell surface proteins. Key surface receptors for platelet adhesion and activation are affected, including the collagen receptor GPVI and the von Willebrand factor receptor, GPIb. PX-12 inhibits thrombus formation over Type I collagen in whole blood under flow conditions[2]. Thioredoxin-1 (Trx-1) is a cellular redox protein that promotes tumor growth, inhibits apoptosis, and up-regulates hypoxia-inducible factor-1α and vascular endothelial growth factor[3]. PX-12 inhibits the growth of colorectal cancer DLD-1 and SW620 cells in a dose- and time-dependent manner. PX-12 reduces cell colony formation and induced a G2/M phase arrest of the cell cycle. PX-12 treatment induces apoptosis. PX-12 inhibits colorectal cancer cell migration and invasion. Treatment of cancer cells with PX-12 reduces NOX1, CDH17 and S100A4 mRNA expression, and increases KLF17 mRNA expression. PX-12 decreases S100A4 protein expression in the colorectal cancer cells[4]. |
| In Vivo | PX-12 has been shown to have in vivo antitumor activity against human tumor xenografts including HT-29 colon cancer in SCID mice and has been tested in a phase I clinical trial in patients[3]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 330.0±25.0 °C at 760 mmHg |
| Molecular Formula | C7H12N2S2 |
| Molecular Weight | 188.314 |
| Flash Point | 153.4±23.2 °C |
| Exact Mass | 188.044189 |
| PSA | 79.28000 |
| LogP | 3.40 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.590 |
| Storage condition | -20℃ |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2933290090 |
| HS Code | 2933290090 |
|---|---|
| Summary | 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |